Arcus Biosciences (NYSE:RCUS) Hits New 1-Year Low – Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS)’s stock price reached a new 52-week low on Wednesday . The company traded as low as $12.83 and last traded at $13.00, with a volume of 305748 shares. The stock had previously closed at $13.09.

Analysts Set New Price Targets

A number of research firms recently issued reports on RCUS. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price for the company. Barclays upped their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. HC Wainwright reissued a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Arcus Biosciences currently has a consensus rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Price Performance

The stock has a market capitalization of $1.20 billion, a PE ratio of -4.15 and a beta of 0.87. The company has a 50-day moving average of $15.25 and a 200 day moving average of $15.89. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.06. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business’s revenue was up 50.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.94) earnings per share. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.2 EPS for the current year.

Insider Buying and Selling

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.30% of the stock is owned by company insiders.

Institutional Trading of Arcus Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new position in Arcus Biosciences during the 4th quarter worth $26,000. Point72 Hong Kong Ltd purchased a new position in shares of Arcus Biosciences during the third quarter worth about $47,000. Point72 DIFC Ltd acquired a new position in Arcus Biosciences in the 2nd quarter valued at about $83,000. Quest Partners LLC raised its stake in Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Arcus Biosciences during the 3rd quarter worth approximately $244,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.